Immunotherapy with these immune checkpoint inhibitors appears to shrink tumors in a greater number of patients across a wider range of tumor types. Hence, PD‐L1 inhibitors are considered to be the most promising drug category for many different cancers 6. Here, CD274 is linked to neoplasm.